



# Next-Gen Cytokine Therapeutics Summit

**Advancing The Next Generation Of Cytokine Therapeutics**

---

November 3<sup>rd</sup>, 2020 | EST Timezone

## **Networking Available All Day**

9:00am - 6:00pm

As the main agenda progresses throughout the day, you will have the choice of listening in to / participating in the live content or spend more of your time networking with your peers.

Here is how you will be able to achieve this, outside of the networking sessions on the agenda

- **See who's in the room** - you will be able to message all live attendees and connect with those who respond.
- **Schedule 1-2-1 video calls** with your connections at any time that suits you.
- **Open Networking** - think of this as the event lobby where you can replicate those all-important "water-cooler" moments.

You will be able to hop seamlessly between networking and on-going agenda sessions at any point.

With networking available all day, this will provide you with even more opportunities to meet your potential future partners and collaborators.

### **Conference Day 1: Tuesday, November 3<sup>rd</sup> 2020**

#### **8:00am Conference Platform Opens**

The conference platform opens before the agenda starts, giving you time to plug the presentations, panels and discussions into your agenda for the rest of the day. This also gives you plenty of time to get familiar with the platform.

**Location: Stage**

#### **Understanding Mechanisms of Action**

#### **9:00am Chair's Opening Remarks**

- A brief overview of the progress made so far in the cytokine therapeutic industry.
- A look at the day ahead - what will be the key takeaways we should achieve by the end of this summit?

**Willem Overwijk**, VP, Oncology Research, **Nektar Therapeutics**

9:05am Keynote Presentation - **Mechanism Of Action Of Bempegaldesleukin, An Engineered IL-2 Agonist.**

- We learn more about the mechanism of action of bempegaldesleukin in immuno oncology
- An overview of clinical results with PD-1 checkpoint blockade in melanoma and other tumor types.

**Willem Overwijk**, VP, Oncology Research, **Nektar Therapeutics**

**Adi Diab**, Associate Professor, Lead Investigator, bempegaldesleukin Clinical Program, **MD Anderson Cancer Center**

9:45am **Wellness Break**

Get-up and have a stretch before the next session begins.

9:50am Presentation: **Designer Superkines: Modulating Immune Cells of Choice**

- Introduce directed evolution to generate a library of superkines with site-specific binding and selectivity
- Discover how Medicenna's super-agonists and antagonists can re-balance the tumor microenvironment
- Learn about Medicenna's Long Acting Interleukin-2 Super-agonist

**Fahar Merchant**, President & CEO, **Medicenna**

10:15am **Wellness Break**

Get-up and have a stretch before the next session begins.

## Location: Sessions

### 10:20am Interactive Panel Q&A - **How Do We Overcome The Major Roadblocks of Cytokine Therapeutics?**

*In the 1990's cytokine therapeutics had their first wave of innovation and development, but key challenges facing the safety profiles of immunocytokines brought their development to a halt. 30 years on, we are now facing the next generation of cytokine therapeutics as adverse clinical effects are being overcome. But do we have a full understanding of the mechanisms of action behind these cytokines and where is the industry currently in this new wave of development? This panel discusses the industry's progress made so far and the challenges ahead.*

- Do we fully understand the mechanisms of action for cytokines?
- Have clinical programs identified an interleukin which offers most clinical promise?
- Is there a way to identify which patients are most likely to benefit from immunocytokine treatment?
- What are the overarching challenges preventing the successful development of cytokine therapeutics?
- What are the anticipated benefits and consequences of fine tuning interleukin receptor agonists?
- If each panelist could have one question into the R&D of cytokine therapeutics answered, what would it be?

**Daniel-Adriano Silva**, VP, Head of Research, **Neoleukin Therapeutics**

**Matthew Bennett**, Director, Protein Engineering, **Xencor**

**Heather Losey**, Senior Director, Program Lead in Immuno-Oncology, **Alkermes**

**Arnold Gelb**, Executive Director, Clinical Development, **Ziopharm Oncology**

### 10:50am - 11:10am **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert speakers from the previous panel.

**Daniel-Adriano Silva**, VP, Head of Research, **Neoleukin Therapeutics**

**Matthew Bennett**, Director, Protein Engineering, **Xencor**  
**Heather Losey**, Senior Director, Program Lead, Immuno-Oncology, **Alkermes**  
**Arnold Gelb**, Executive Director, Clinical Development, **Ziopharm Oncology**

**Actively or passively take part in this session.**

11:10am **Speed Networking**

In the purpose-built Networking area, get ready to expand your network through randomly assigned 1 on 1 quick-fire video meetings. You can choose who you want to “connect” with and then set-up 1-2-1 in-depth catch-up’s throughout the rest of the event. This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.

Your future collaborators or partners could be just one click away!

**Location: Stage**

**Cytokine Delivery**

11:35am Presentation: **Maximizing The Efficacy Of IL-15 Agonists And Their Mechanisms Of Action.**

- We learn more about the multiple mechanisms being utilised for IL-15.
- Insight into research assessing the effect of systemic and locally-delivered IL-15.

**Kimberly Schluns**, Associate Professor, **MD Anderson Cancer Center**

12:00pm **Wellness Break**

Get-up and have a stretch before the next session begins.

12:05pm Presentation: **OncoSec's Innovative Method to Deliver Cytokine Therapeutics Using Proprietary Electroporation.**

- We hear how OncoSec have negated toxicity using Proprietary Electroporation
- OncoSec shares insights into their current clinical trials for melanoma and triple negative breast cancer.

**Chris Twitty**, Chief Scientific Officer, **OncoSec**

12:30pm

### **Lunch**

Finally, a lunch at a conference that is completely your choice!

Use this extended break to have your regular lunch, spend time with your family and give your brain a break. Recharge for the afternoon session.

---

The Next-Gen Cytokine Therapeutics Summit includes an extended break in the middle to give you ample time for lunch and another chance to catch-up on the day job. Or if you have time, you can use this break for 1-2-1 meetings or open networking.

---

Location: **Expo Area**

2:00pm **Tour of Expo**

Take a tour of the virtual Expo and interact with partners of The Next-Gen Cytokine Therapeutics to understand more about their services.

### **Cytokines in Combination Therapy**

2:20pm Presentation: **NL-201 - Using *De Novo* Protein Design To Overcome Long-Standing Challenges In Cytokine Immunotherapy.**

- We learn more about how Neoleukin's de novo protein design and Neoleukin Platform can aid research and development for cytokine therapeutics.
- An insight into Neoleukin's current lead program NL-201 and its preclinical progress.

**Carl Walkey**, VP, Corporate Development, **Neoleukin Therapeutics**

2:45pm **Wellness Break**

Get-up and have a stretch before the next session begins.

2:50pm Presentation: **ALKS 4230: A Novel Engineered Cytokine, Designed by Alkermes' PICASSO™ Technology**

- Alkermes provides an overview of the molecular design, mechanism of action and preclinical data
- Combination potential of ALKS 4230 with other cancer therapies with complementary mechanisms
- Overview of ALKS 4230 clinical development program and key data

**Heather Losey**, Senior Director, Program Lead, Immuno-Oncology, **Alkermes**

3:15pm **Wellness Break**

Get-up and have a stretch before the next session begins.

### **Controlling and Sustaining Cytokine Release**

3:20pm Presentation: **Next Generation IL15-Fc Fusions Engineered For Superior Therapeutic Index**

- We learn more about Xencor's cytokine-Fc fusions, including their lead IL-15 program XmAb24306 using their engineered heterodimeric antibody Fc domain.
- An insight into the challenges that have arisen whilst creating druggable versions of natural cytokines and how Xencor have precisely tuned their molecules to control and sustain the exposure.

**Matthew Bennett**, Director, Protein Engineering, **Xencor**

3:45pm **Wellness Break**



Catch-up on emails, let the dog out or brew some more coffee - use this time to take care of regular day-to-day life.

### **Controlling and Sustaining Cytokine Release**

4:10pm Presentation: **Ziopharm's Controlled IL-12 Platform and Its Efficacy In Tumors.**

- An insight into Ziopharm's controlled IL-12 platform and its ability to activate a t-cell response.
- A look at the latest progression of IL-12 in Ziopharm's clinical trials for those with glioblastoma, breast cancer and melanoma.

**Arnold Gelb**, Executive Director, Clinical Development, *Ziopharm Oncology*

4:35pm **Wellness Break**

Get-up and have a stretch before the next session begins.

4:40pm Presentation - **Surface-Tethered Cytokine Reservoirs Boost Activity and Efficacy of Adoptive Cell Therapies**

- We will hear how Repertoire Immune Medicines's T cell therapies safely deliver cytokines to tumors for controlled release without major systemic exposure
- We will also learn how Repertoire Immune Medicines' technology sustains anti-tumor immunity for superior efficacy.

**Douglas Jones**, Director, Biotherapeutic Discovery and Research, *Repertoire Immune Medicines*

5:05pm **Wellness Break**

Get-up and have a stretch before the next session begins.

### **Location: Sessions**

5:10pm Panel Discussion: **Walking the Efficacy/Toxicity Tightrope - Can We Achieve The Perfect Balance?**

*Adverse clinical effects were largely responsible for the failure of previous cytokine therapeutics. With such promising programs showcased today, how can we ensure toxicity does not prevent the success of this next generation of cytokine therapeutics? This panel addresses our current understanding for minimizing the toxicities and discusses where we need to maximize the efficacies for successful cytokine therapeutics.*

- Do we have a full understanding of what causes toxicity?
- How do we separate toxicity from desired cytokine activity?
- Do we face a double dilemma? - Is it possible to sustain the presence of cytokine therapies to enable the controlling and focusing of effects in the tumor microenvironment?
- What are the mechanisms and engineering approaches to improve the efficacy and tolerability of cytokines?
- How can we modulate cytokines to dial out and prevent toxicity, whilst focusing beneficial cytokine activity?
- How can we optimize cytokine delivery and dosing regimen to optimize efficacy while avoiding toxicities? Is tachyphylaxis commonly observed, and is it a blessing or a curse?

**Kimberly Schluns**, Associate Professor, **MD Anderson Cancer Center**

**Douglas Jones**, Director, Biotherapeutic Discovery and Research, **Repertoire Immune Medicines**

**Willem Overwijk**, VP, Oncology Research, **Nektar Therapeutics**

**Khaled Ali**, Senior Scientist, **Amgen**

**Location: Networking & Sessions**

5:30pm - 6:30pm **Virtual Drinks**

Share a virtual drink with old friends or new connections. At small virtual tables, this is your chance to casually interact with the rest of the industry.

Hosted by **Nektar Therapeutics**

5:30pm - 5:50pm **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert speakers from the previous panel.

**Kimberly Schluns**, Associate Professor, **MD Anderson Cancer Center**

**Douglas Jones**, Director, Biotherapeutic Discovery and Research,  
**Repertoire Immune Medicines**

**Willem Overwijk**, VP, Oncology Research, **Nektar Therapeutics**

**Khaled Ali**, Senior Scientist, **Amgen**

**Actively or passively take part in this session.**

6:00pm **Close of The Next-Gen Cytokine Therapeutics Summit**

Roll straight into the rest of your Tuesday with no flight to catch!